6071-93-8

Basic information

• Product Name: 4-(diphenylmethylidene)-1-methylpiperidine
• Synonyms: 4-(Diphenylmethylene)-1-methylpiperidine; piperidine, 4-(diphenylmethylene)-1-methyl-
• CAS NO: 6071-93-8
• Molecular Formula: C₁₉H₂₁N
• Molecular Weight: 263.3767
• Mol File: 6071-93-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 399.7°C at 760 mmHg
• Flash Point: 174.7°C
• Density: 1.046g/cm³
• Vapor Pressure: 1.34E-06mmHg at 25°C
• Refractive Index: 1.59
• CAS DataBase Reference: 4-(diphenylmethylidene)-1-methylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(diphenylmethylidene)-1-methylpiperidine(6071-93-8)
• EPA Substance Registry System: 4-(diphenylmethylidene)-1-methylpiperidine(6071-93-8)

Safety Data

• Hazardous Substances Data: 6071-93-8(Hazardous Substances Data)

Upstream product

• 119-61-9 benzophenone 
• 591-51-5 phenyllithium 
• 1690-75-1 1-methyl-piperidine-4-carboxylic acid methyl ester 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 5570-77-4 4-chloro-1-methylpiperidine 
• 102449-34-3 4-diphenylmethylene-1-piperidinecarboxylic acid ethyl ester 
• 6071-92-7 VUF 4589 

Downstream Products

• 102449-34-3 4-diphenylmethylene-1-piperidinecarboxylic acid ethyl ester 
• 688304-93-0 6-(4-Benzhydrylidene-piperidin-1-yl)-hexanoic acid methyl ester 
• 137406-19-0 5-(4-Benzhydrylidene-piperidin-1-yl)-pentanoic acid ethyl ester 
• 137406-18-9 4-(4-Benzhydrylidene-piperidin-1-yl)-butyric acid ethyl ester 
• 137406-16-7 3-(4-Benzhydrylidene-piperidin-1-yl)-propionic acid ethyl ester 
• 167108-56-7 (4-Benzhydrylidene-piperidin-1-yl)-acetic acid ethyl ester 
• 50706-57-5 4-(diphenylmethylene)piperidine 
• 100169-94-6 1,1-dimethyl-4-(diphenylmethylene)piperidinium iodide 
• 5704-22-3 4-(diphenylmethyl)-1-methylpiperidine 

Relevant articles and documents

Steric structure–activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9

Set7/9 is a histone lysine methyltransferase, but it is also thought to be involved in a wide variety of pathophysiological functions. We previously identified cyproheptadine, which has a characteristic butterfly-like molecular conformation with bent tricyclic dibenzosuberene and chair-form N-methylpiperidine moieties, as a Set7/9 inhibitor. In this work, we synthesized several derivatives in order to examine the steric structure–inhibitory activity relationship. We found that even a small change of molecular shape due to reduction or replacement of the 10,11-olefinic bond of the tricyclic ring generally resulted in a drastic decrease of the inhibitory activity. Our results should be useful not only for development of more potent and selective inhibitors, but also for the construction of novel inhibitor scaffolds.

TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS

The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.

Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer

The effect of 24 newly synthesized quinoline derivatives on tumor cell multidrug resistance (MDR) was examined in vitro. At low concentrations, these compounds enhanced the accumulation of [3H]vincristine in K562/ADM cells and reversed tumor cell MDR. The results of the structure-activity relationship analysis indicate that in highly active compounds the two aryl rings in the hydrophobic moiety deviate from a common plane, so they are capable of interacting with hydrogen bond donors of P-170 glycoprotein (P- gp) via π-hydrogen-π interactions. Other major structural features which influence the MDR-reversing activities of these compounds are a quinoline nitrogen atom and a basic nitrogen atom in piperazine. Furthermore, in highly active compounds, the distance between the hydrophobic moiety and the basic nitrogen atom (an atom connected to 2-hydroxypropoxyquinoline) must be at least 5 A?. Several compounds were found to reverse vincristine resistance in K562/ADM cells in vitro, and compound 16 (MS-209) was selected for clinical studies.